Blood-Clot Drug Buyers Seek Class Cert. In Antitrust Suit

By Matthew Perlman · November 19, 2018, 8:11 PM EST

Indirect purchasers of blood clot drug Lovenox and its generic version asked a Tennessee federal court for class certification in their suit alleging Momenta Pharmaceuticals Inc. and Sandoz Inc. conspired to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Certify Class

Case Information

Case Title

The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee v. Momenta Pharmaceuticals, Inc. et al

Case Number

Court

Tennessee Middle

Nature of Suit

Anti-Trust

Date Filed

October 14, 2015

Recent Articles By Matthew

April 14, 2025
Takeda Gets Actos Case Paused For Class Cert. Review
April 07, 2025
Monthly Merger Review Snapshot
April 02, 2025
Serial Acquisitions Are Still On The FTC's Radar
April 01, 2025
Takeda Antitrust Trial Over Actos Generics Set For July
March 28, 2025
PE Firm Hits Back Against Medical Device Coating Challenge
March 27, 2025
DOJ's Antitrust Unit Targeting Anticompetitive Regulations
March 20, 2025
8th Circ. Won't Pause FTC's Insulin Pricing Case
March 17, 2025
Court Won't Toss Biotech Co.'s Antitrust Counterclaim
March 14, 2025
FTC Urges 8th Circ. Not To Pause Insulin Pricing Case
March 13, 2025
Calif. AG Appealing State Limits On Pay-For-Delay Ban